In our exploratory analysis of repeat testing in 2-week windows (Table S1), 30% to 40% of women had symptoms or signs of preeclampsia at repeat testing visits, 16% to 32% of women changed from normal to abnormal PlGF-based test category, 2% to 6% changed to very abnormal PlGF-based test category, and 5% to 8% of women were diagnosed with preeclampsia in each 2-week window. This evidence concerns the gene PGF and preeclampsia.